KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?

KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?

KRAS genotyping is mandatory in metastatic colorectal cancer treatment prior to undertaking antiepidermal growth factor receptor (EGFR) monoclonal antibody therapy. BRAF V600E mutation is often present in colorectal carcinoma with CpG island methylator phenotype and microsatellite instability. Curre...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicolas Piton, Francesco Borrini, Antonio Bolognese, Aude Lamy, Jean-Christophe Sabourin
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2015/753903
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items